康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1681)

Voluntary Announcement
Notice of Approval for Clinical Trial of Drug for SK-07 Injection

This announcement is made by Consun Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has received the "Notice of Approval for Clinical Trial of Drug* (《藥物臨床試驗批准通知書》)" issued by the National Medical Products Administration ("**NMPA**") in relation to the approval of the clinical trial application for SK-07 injection ("**SK-07**"). The relevant information is hereby announced as follows:

Drug name:	SK-07 injection
Application:	Registration of clinical trial of pharmaceutical product
Acceptance number:	CXHL2300090
Applicant:	Guangzhou Consun Pharmaceutical Company Limited* (廣州康臣藥業有限公司) (a wholly-owned subsidiary of the Company)
Review conclusion:	In accordance with the Drug Administration Law of the People's Republic of China* (《中華人民共和國藥品管理法》) and the relevant regulations, upon review, the application for clinical trial of SK-07 injection, which was accepted for processing on 17 January 2023, meets the relevant requirements for drug registration and it is approved that the clinical trial of this product can be commenced. Indication for the application: treatment of uremia pruritus.

About SK-07

SK-07 is a new generation of class I drug to treat uremia pruritus, which was jointly developed by the Group and WuXi AppTec (Shanghai) Co., Ltd.* (上海藥明康德新藥開發有限公司). After obtaining the aforementioned approval from NMPA, clinical trials will be launched soon.

Uremia pruritus is a common clinical complication in hemodialysis patients. About 40% -50% of patients with chronic renal failure who undergo regular dialysis treatment will experience skin itching. At present, there is no specific treatment drug for uremia pruritus, and there is no unified treatment standard in China. Uremia pruritus has a huge blank market with significant unmet clinical needs. Our company will continue to actively promote clinical trials of SK-07 and strive to put it on the market as soon as possible for the benefit of patients.

As there are significant risks and uncertainties in the process of research, development and commercialization of pharmaceutical products, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. The Company will actively pursue the above-mentioned research and development projects and will comply with its obligations to disclose information on the subsequent progress of the projects in a timely manner in strict accordance with the relevant regulations.

By order of the Board of
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 16 April 2023

As at the date of this announcement, the Board comprises Mr. An Meng, Ms. Li Qian, Professor Zhu Quan and Mr. Xu Hanxing as executive directors; Ms. Zhang Lihua as a non-executive director; and Mr. Su Yuanfu, Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive directors.

* *For identification purpose only*